Compounds > ucm 454
Page last updated: 2024-11-12

ucm 454

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Cross-References

ID SourceID
PubMed CID10428383
CHEMBL ID33185
MeSH IDM0486583

Synonyms (12)

Synonym
n-((1-(4-chlorobenzyl)-4-methoxy-1h-indol-2-yl)methyl)propionamide
bdbm50240442
n-[1-(4-chloro-benzyl)-4-methoxy-1h-indol-2-ylmethyl]-propionamide
CHEMBL33185 ,
ucm 454
gtpl7783
ucm454
n-[[1-[(4-chlorophenyl)methyl]-4-methoxyindol-2-yl]methyl]propanamide
cid 10428383
Q27089057
364629-05-0
AKOS040754289
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Melatonin receptor type 1AHomo sapiens (human)Ki1.28910.00000.27359.1000AID107894; AID1138147; AID239989; AID369281
Melatonin receptor type 1BHomo sapiens (human)Ki0.00880.00000.16289.1000AID108055; AID1138148; AID239966; AID369282
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (18)

Processvia Protein(s)Taxonomy
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMelatonin receptor type 1AHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayMelatonin receptor type 1AHomo sapiens (human)
mating behaviorMelatonin receptor type 1AHomo sapiens (human)
circadian rhythmMelatonin receptor type 1AHomo sapiens (human)
G protein-coupled receptor signaling pathwayMelatonin receptor type 1AHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMelatonin receptor type 1BHomo sapiens (human)
chemical synaptic transmissionMelatonin receptor type 1BHomo sapiens (human)
negative regulation of cGMP-mediated signalingMelatonin receptor type 1BHomo sapiens (human)
glucose homeostasisMelatonin receptor type 1BHomo sapiens (human)
camera-type eye developmentMelatonin receptor type 1BHomo sapiens (human)
negative regulation of neuron apoptotic processMelatonin receptor type 1BHomo sapiens (human)
negative regulation of vasoconstrictionMelatonin receptor type 1BHomo sapiens (human)
positive regulation of circadian sleep/wake cycle, non-REM sleepMelatonin receptor type 1BHomo sapiens (human)
negative regulation of insulin secretionMelatonin receptor type 1BHomo sapiens (human)
regulation of insulin secretionMelatonin receptor type 1BHomo sapiens (human)
negative regulation of cytosolic calcium ion concentrationMelatonin receptor type 1BHomo sapiens (human)
negative regulation of transmission of nerve impulseMelatonin receptor type 1BHomo sapiens (human)
positive regulation of transmission of nerve impulseMelatonin receptor type 1BHomo sapiens (human)
regulation of neuronal action potentialMelatonin receptor type 1BHomo sapiens (human)
G protein-coupled receptor signaling pathwayMelatonin receptor type 1BHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (5)

Processvia Protein(s)Taxonomy
protein bindingMelatonin receptor type 1AHomo sapiens (human)
melatonin receptor activityMelatonin receptor type 1AHomo sapiens (human)
hormone bindingMelatonin receptor type 1AHomo sapiens (human)
organic cyclic compound bindingMelatonin receptor type 1AHomo sapiens (human)
G protein-coupled receptor activityMelatonin receptor type 1AHomo sapiens (human)
protein bindingMelatonin receptor type 1BHomo sapiens (human)
melatonin receptor activityMelatonin receptor type 1BHomo sapiens (human)
G protein-coupled receptor activityMelatonin receptor type 1BHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (3)

Processvia Protein(s)Taxonomy
plasma membraneMelatonin receptor type 1AHomo sapiens (human)
receptor complexMelatonin receptor type 1AHomo sapiens (human)
plasma membraneMelatonin receptor type 1AHomo sapiens (human)
plasma membraneMelatonin receptor type 1BHomo sapiens (human)
synapseMelatonin receptor type 1BHomo sapiens (human)
plasma membraneMelatonin receptor type 1BHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (17)

Assay IDTitleYearJournalArticle
AID108023Relative Binding Affinity (pRA1) to cloned human Melatonin receptor type 1A, stably expressed in NIH3T3 rat fibroblast cells, determined using 2-[125I]iodomelatonin2003Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8
Three-dimensional quantitative structure-activity relationship studies on selected MT1 and MT2 melatonin receptor ligands: requirements for subtype selectivity and intrinsic activity modulation.
AID239966Inhibition of 2-[125I]iodomelatonin binding to human melatonin receptor MT2 expressed in NIH3T3 rat fibroblast cells2005Journal of medicinal chemistry, Jun-16, Volume: 48, Issue:12
Analysis of structure-activity relationships for MT2 selective antagonists by melatonin MT1 and MT2 receptor models.
AID239989Inhibition of 2-[125I]iodomelatonin binding to human melatonin receptor type 1A (MT1) expressed in NIH3T3 rat fibroblast cells2005Journal of medicinal chemistry, Jun-16, Volume: 48, Issue:12
Analysis of structure-activity relationships for MT2 selective antagonists by melatonin MT1 and MT2 receptor models.
AID108040Relative Intrinsic activity evaluated on [35S]GTP-gamma-S, binding in NIH3T3 cells stably transfected with human Melatonin receptor type 1B2003Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8
Three-dimensional quantitative structure-activity relationship studies on selected MT1 and MT2 melatonin receptor ligands: requirements for subtype selectivity and intrinsic activity modulation.
AID108056Relative Binding Affinity (pRA1) to cloned human Melatonin receptor type 1B, stably expressed in NIH3T3 rat fibroblast cells, determined using 2-[125I]iodomelatonin2003Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8
Three-dimensional quantitative structure-activity relationship studies on selected MT1 and MT2 melatonin receptor ligands: requirements for subtype selectivity and intrinsic activity modulation.
AID1138147Antagonist activity at human MT1 receptor2014Journal of medicinal chemistry, Apr-24, Volume: 57, Issue:8
MT1 and MT2 melatonin receptors: ligands, models, oligomers, and therapeutic potential.
AID233512The difference (pKi1-pKi2) represents selectivity towards the melatonin receptors MT1 (positive values ) or the MT2 (negative values) subtype2001Journal of medicinal chemistry, Aug-30, Volume: 44, Issue:18
2-N-acylaminoalkylindoles: design and quantitative structure-activity relationship studies leading to MT2-selective melatonin antagonists.
AID107872The relative intrinsic values (IAr) obtained by dividing the maximal analogue-induced G-protein activation by that of melatonin-12001Journal of medicinal chemistry, Aug-30, Volume: 44, Issue:18
2-N-acylaminoalkylindoles: design and quantitative structure-activity relationship studies leading to MT2-selective melatonin antagonists.
AID369282Displacement of 2-[125I]iodomelatonin from human MT2 receptor expressed in CHO cells2009Journal of medicinal chemistry, Feb-12, Volume: 52, Issue:3
2-[(2,3-dihydro-1H-indol-1-yl)methyl]melatonin analogues: a novel class of MT2-selective melatonin receptor antagonists.
AID369281Displacement of 2-[125I]iodomelatonin from human MT1 receptor expressed in CHO cells2009Journal of medicinal chemistry, Feb-12, Volume: 52, Issue:3
2-[(2,3-dihydro-1H-indol-1-yl)methyl]melatonin analogues: a novel class of MT2-selective melatonin receptor antagonists.
AID107894Binding affinity towards melatonin receptor type 1A stably expressed in NIH3T3 rat fibroblast cells using 2-[125I]iodomelatonin (100 pM) as radioligand2001Journal of medicinal chemistry, Aug-30, Volume: 44, Issue:18
2-N-acylaminoalkylindoles: design and quantitative structure-activity relationship studies leading to MT2-selective melatonin antagonists.
AID238023Intrinsic activity in [35S]GTP-gamma-S, binding at human melatonin receptor MT2 relative to melatonin2005Journal of medicinal chemistry, Jun-16, Volume: 48, Issue:12
Analysis of structure-activity relationships for MT2 selective antagonists by melatonin MT1 and MT2 receptor models.
AID108036The relative intrinsic values (IAr) of melatonin receptor type 1B obtained by dividing the maximal analogue-induced G-protein activation by that MLT.2001Journal of medicinal chemistry, Aug-30, Volume: 44, Issue:18
2-N-acylaminoalkylindoles: design and quantitative structure-activity relationship studies leading to MT2-selective melatonin antagonists.
AID1138148Antagonist activity at human MT2 receptor2014Journal of medicinal chemistry, Apr-24, Volume: 57, Issue:8
MT1 and MT2 melatonin receptors: ligands, models, oligomers, and therapeutic potential.
AID107876Relative Intrinsic activity evaluated on [35S]GTP-gamma-S, binding in NIH3T3 cells stably transfected with human Melatonin receptor type 1A2003Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8
Three-dimensional quantitative structure-activity relationship studies on selected MT1 and MT2 melatonin receptor ligands: requirements for subtype selectivity and intrinsic activity modulation.
AID108055Binding affinity towards melatonin receptor type 1B stably expressed in NIH3T3 rat fibroblast cells using 2-[125I]iodomelatonin2001Journal of medicinal chemistry, Aug-30, Volume: 44, Issue:18
2-N-acylaminoalkylindoles: design and quantitative structure-activity relationship studies leading to MT2-selective melatonin antagonists.
AID1346274Human MT2 receptor (Melatonin receptors)2005Journal of medicinal chemistry, Jun-16, Volume: 48, Issue:12
Analysis of structure-activity relationships for MT2 selective antagonists by melatonin MT1 and MT2 receptor models.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (80.00)29.6817
2010's1 (20.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
melatonin
[no description available]		3.1350acetamides;
tryptamines		anticonvulsant;
central nervous system depressant;
geroprotector;
hormone;
human metabolite;
immunological adjuvant;
mouse metabolite;
radical scavenger
n-acetylserotonin
N-acetylserotonin : An N-acylserotonin resulting from the formal condensation of the primary amino group of serotonin with the carboxy group of acetic acid.		2.0110acetamides;
N-acylserotonin;
phenols		antioxidant;
human metabolite;
mouse metabolite;
tropomyosin-related kinase B receptor agonist
6-chloromelatonin
[no description available]		2.4520acetamides
n-acetyltryptamine
N-acetyltryptamine: antagonizes the melatonin-induced inhibition of dopamine release from retina; RN given refers to parent cpd. N-acetyltryptamine : A tryptamine compound having an acetyl substituent attached to the side-chain amino function.		2.0110acetamides;
indoles
2-iodomelatonin
[no description available]		2.4520acetamides
luzindole
luzindole: melatonin receptor antagonist; structure given in first source. luzindole : A member of the class of indoles that is tryptamine in which one of the amino hydrogens is replaced by an acetyl group while the hydrogen at position 2 is replaced by a benzyl group.		2.4520acetamides;
indoles		melatonin receptor antagonist
2-bromomelatonin
2-bromomelatonin: structure given in first source		2.0110
5-methoxyluzindole
[no description available]		2.110
ramelteon
ramelteon: melatonin MT1/MT2 receptor agonist		2.110indanes
4-phenyl-2-propionamidotetraline
4-phenyl-2-propionamidotetraline: melatonin receptor antagonist; structure in first source		2.9540tetralins
2-phenylmelatonin
[no description available]		2.0110phenylindole
iik7
IIK7: structure in first source		2.4520
k 185
[no description available]		2.7430
n-butanoyl-5-methoxytryptamine
N-butanoyl-5-methoxytryptamine: mimics melatonin's antigonadal activity and inhibits 2-iodomelatonin binding		2.0110
ConditionIndicatedRelationship StrengthStudiesTrials
Depression, Endogenous
[description not available]		02.110
Chronic Insomnia
[description not available]		02.110
Depressive Disorder
An affective disorder manifested by either a dysphoric mood or loss of interest or pleasure in usual activities. The mood disturbance is prominent and relatively persistent.		02.110
Sleep Initiation and Maintenance Disorders
Disorders characterized by impairment of the ability to initiate or maintain sleep. This may occur as a primary disorder or in association with another medical or psychiatric condition.		02.110